Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Clarification: Vol. 52, No. 10
In the notice to readers, "FDA Licensure of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), and Poliovirus Vaccine Combined (PEDIARIX) for Use in Infants," there were two potentially misleading statements in the paragraph following the heading "ACIP Approval for DTaP-HepB-IPV for the
Vaccine for Children Program." First, the statement "3 doses of PEDIARIX can be administered to an infant who is born to a woman who
is hepatitis B surface antigen (HBsAg)-positive or whose HBsAg status is unknown" is
potentially misleading. A birth dose of single-antigen vaccine is preferred for all infants but must be administered to infants who are born to women who are HBsAg-positive or whose HBsAg status is unknown. The birth dose can then be followed by 3 doses of PEDIARIX at
ages 2, 4, and 6 months. Second, the third dose of PEDIARIX should be administered at least 16 weeks after the first dose
and at least 8 weeks after the second dose but not before age 6 months.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
